

**DAVAINDIA HEALTH MART LIMITED**

**Registered Office:** Shop No. G 44 Ayappa Ind, Zota House, Bhedwad, Choryasi, Surat – 394220,  
Gujarat

**CIN:** U24110GJ2020PLC111827

**Email:** info@zotahealthcare.com **Ph No.:** 0261-2331601 **website:** www.davaindia.com

---

**NOTICE OF THE 5<sup>th</sup> ANNUAL GENERAL MEETING**

Notice is hereby given that the 5th Annual General Meeting of the Members of Davaindia Health Mart Limited will be held on Monday, September 30, 2024 at 11:00 A.M. at Zota House, 2/896 Hira Modi Street, Sagrampura, Surat – 395002, Gujarat to transact the following businesses:

**ORDINARY BUSINESS:**

1. To receive, consider & adopt the Audited Financial Statements of the Company for the financial year ended on March 31, 2024, together with the reports of the board of Directors and the Auditor thereon.
2. To appoint a director in place of Mr. Viren Manukant Zota, Director (DIN: 08656333) who retires by rotation in terms of section 152(6) of the Companies Act, 2013; and being eligible offers himself to be re-appointed.

**SPECIAL BUSINESSES:**

3. **To Change the terms of Appointment of Mr. Harkishan Ambaram Jani (DIN-10247676), Executive Director of the Company:**

To consider and if through fit, to pass with or without modification, the following resolution as **Special Resolution**:

**“RESOLVED THAT** pursuant to the provisions of Section 196, 197 & 198 read with Schedule V of the Companies Act, 2013 and all other applicable provisions of the Companies Act, 2013 (“Act”) and the Companies (Appointment and Qualification of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof for the time being in force) and any other applicable laws, if any, pursuant to recommendation of Board of Directors of the Company and in furtherance to special resolution passed in the 4th Annual General Meeting held on September 30, 2023, consent of the members be and is hereby accorded for revision in remuneration payable to Mr. Harkishan Ambaram Jani (DIN-10247676), Executive Director of the Company, as set out below with effect from October 01, 2024 for the remaining period of his present term of appointment up to July 31, 2028, Company shall pay to Mr. Harkishan Ambaram Jani remuneration as set out below:

**(1) Remuneration:** In the scale of ₹ 12,00,000/- to ₹ 24,00,000/- per annum w.e.f. October 01, 2024 to July 31, 2028, basis annual performance evaluation by the Board (including any committee formed thereunder from time to time) to increase the same from time to time within the aforesaid range provided it remains in accordance with the limits specified in Schedule V of the Companies Act, 2013, as amended from time to time. The annual or other increments will be merit based and will take into account the Company’s performance apart from individual’s performance;

**(2) Sitting Fees:** NIL”

**“RESOLVED FURTHER THAT** in case of loss or inadequate profit Mr. Harkishan Ambaram Jani shall be entitled to receive the remuneration as stated above as the Minimum Remuneration.”

**“RESOLVED FURTHER THAT** all other terms of appointment shall be same as per appointment made in the 4<sup>th</sup> Annual General Meeting held on September 30, 2023.”

**"RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, any Director of the Company be and is hereby authorised to do all acts, deeds, matters and things necessary, proper or desirable and to sign and execute all necessary documents, applications and returns along with filing of necessary E-form with ROC."

**4. To Appoint Mr. Vitrag Sureshkumar Modi (DIN-08457204) as Non-Executive Independent Director of the Company:**

To consider and if through fit, to pass with or without modification, the following resolution as **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Section 149, 150 and 152 read with Schedule IV of the Companies Act, 2013 and all other applicable provisions of the Companies Act, 2013 ("Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof for the time being in force) and any other applicable laws, if any, consent of the members be and is hereby accorded to appoint Mr. Vitrag Sureshkumar Modi (DIN No.: 08457204), who was appointed as an Additional Director designated as Non-Executive Independent Director on the Board of Directors of the Company w.e.f. August 28, 2024, in terms of Section 161 of the Companies Act, 2013 and who holds office up to the date of this ensuing Annual General Meeting, be and is hereby appointed as Non-Executive Independent Director of the Company for the period of five consecutive years starting from August 28, 2024 to August 27, 2029 at following terms and conditions:

- (1) **Period of appointment:** Appointment for a term of five consecutive years commencing from August 28, 2024 to August 27, 2029;
- (2) **Remuneration:** NIL;
- (3) **Sitting Fees:** ₹ 5000/- per meeting for attending meeting of the Board or Committees thereof."

**"RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to do all acts and to take all such steps as may be necessary, proper or expedient to give effect to this resolution."

Place: SURAT  
Date: 07.09.2024

By order of the board for  
**DAVAINDIA HEALT MART LIMITED**

Sd/-  
**Himanshu Muktilal Zota**  
(Director)  
DIN: 01097722

**NOTES:**

1. A member entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy to attend and vote on poll on his/ her behalf and the proxy need not be a member of the company. Pursuant to Section 105 of Companies Act, 2013, a person can act as proxy on behalf of not more than fifty members holding in aggregate, not more than ten percent of the total share capital of the Company. Members holding more than ten percent of the total share capital of the Company may appoint a single person as a proxy who shall not act as a proxy for any other member. The instrument of proxy, in order to be effective, should be deposited at the registered office of the Company, duly completed and signed, not later than forty-eight hours before the commencement of the meeting. A proxy form is annexed to this report. Proxies submitted on behalf of limited Companies, Societies, etc, must be supported by an appropriate resolution / authority, as applicable.

2. Corporate Members intending to send their authorized representative to attend the Annual General Meeting, pursuant to Section 113 of the Companies Act, 2013 are requested to send to the Company, a certified copy of relevant Board resolution together with the respective specimen signatures of
3. The Notice of Annual General Meeting along with Proxy Form and Attendance Slip, are being sent to all the members by the permitted mode.
4. The Prominent land mark near venue of AGM is Gujarat Samachar Press and next to Navsarjan Hospital. Map and Venue of AGM is as follows:



5. The Explanatory Statement according to Section 102 of the Act setting out material facts concerning the special businesses under Item Nos. 3 and 4 of the Notice is annexed hereto.
6. All documents referred in the notice and the accompany explanatory statement are open for inspection at the Registered Office of the Company during office hours on all days except Sunday & Public holidays between 11:00 a.m. and 1.00 p.m. up to the date of Annual General Meeting.
7. Members / Proxies / Authorised Representatives are requested to bring to the Meeting necessary details of their shareholding, attendance slip(s) and copy (ies) of Annual Report.
8. Members who have not yet registered their email addresses are requested to register the same with their DPs.
9. The details of directors appointment or re-appointment/ revision in remuneration as required under Secretarial Standards on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI) is as below:

Name of Director	Mr. Viren Manukant Zota (DIN: 08656333)	Mr. Harkishan Ambaram Jani (DIN: 10247676)	Mr. Vitrag Sureshkumar Modi (DIN No.: 08457204)
D.O.B	30/05/1984	01/06/1977	21/01/1990
Age (in years)	40 years	47	34 years
Brief resume of the Director including nature of expertise in specific functional areas and Experience	Mr. Viren Manukant Zota is an accomplished professional holding a Bachelor's in Business Administration (BBA) from B.R.C.M. College, Surat. Following his education, Mr. Viren immediately delved into the world of Franchisee Marketing, where he	Mr. Harkishan Ambaram Jani has done Diploma in Pharmacy in the year of 1997 from the Bhavnagar University. Mr. Harkishan's experience in pharmacy business spans over 20 years in several company including Apollo Hospitals Enterprises	Mr. Vitrag Sureshkumar Modi is practicing Chartered Accountant. He is a fellow member of the Institute of Chartered Accountant of India (ICAI). He has completed the Chartered Accountancy course in the year 2011. He has also done Bachelor of Commerce from the Veer

	<p>embarked on a hands-on journey across various regions of India. Through this immersive experience, he gained invaluable insights into the nuances of the last point of sale, laying the groundwork for his subsequent achievements.</p> <p>At present Mr. Viren Manukant Zota serves as Director of the Company. He is in charge of overall management.</p>	<p>Limited, Gujarat and Aristo Pharmaceuticals Ltd. Occupying senior management and executive positions, his experience encompasses a broad range of pharmacy specific activities. He possess a strong command over operational activities relating to retail pharmacy.</p> <p>He is also associated with the Company as an Executive Director since last 1 year and he is taking care of operations of COCO stores and overall management.</p>	<p>Narmad South Gujarat University, Surat in the year 2010. In the year 2017, he has formed his own firm and doing practice. So, he is having total work experience of around thirteen years. His core areas of working are Direct and Indirect Taxes, Bank Audits, Management and System Audit, Accounting and Corporate Services.</p>
<b>Date of Appointment (DD/MM/YYYY) and remuneration last drawn by such person</b>	<p>01/01/2020</p> <p>Last Drawn Remuneration: NIL</p>	<p>01/08/2023</p> <p>Last Drawn Remuneration: Rs. 6.80 lakhs</p>	<p>28/08/2024</p>
<b>Qualification</b>	Bachelor of Business Administration (BBA)	D.Pharmcy	Bachelor of Commerce (B.Com), Chartered Accountant (CA)
<b>Number of Equity Shares held in the Company</b>	1	NIL	NIL
<b>Number of Board Meetings attended during the Financial Year 2023-24</b>	9	7	NIL
<b>Directorships held in other Companies</b>	1	NIL	1
<b>Chairmanships of Committees in other Companies</b>	NIL	NIL	1
<b>Memberships of Committees in other Companies</b>	NIL	NIL	NIL
<b>Relationships between Directors of the Company inter-se</b>	N.A.	N.A.	N.A.
<b>Terms and conditions of appointment / reappointment along with details of remuneration sought to be paid</b>	Re-appointed as a Non-Executive Director, liable to retire by rotation. He does not receive any remuneration from the Company.	As detailed in the explanatory statement to item no. 3 of the Notice	As detailed in the explanatory statement to item no. 4 of the Notice

#### EXPLANATORY STATEMENT IN RESPECT OF SPECIAL BUSINESSES PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

##### Item No. 3:

Mr. Harkishan Ambaram Jani (DIN: 10247676) was appointed as an Executive Director of the Company with effect from August 01, 2023 for period of five years upto July 31, 2028 by way of a special resolution passed by the members at the 4th Annual General Meeting of the Company held on September 30, 2023. Further, in the

aforesaid members meeting, the members of the Company have also approved the remuneration of Rs. 85000/- per month payable to Mr. Harkishan Ambaram Jani.

Mr. Harkishan Ambaram Jani has provided dedicated services and significant contribution to the overall growth of the Company. The Board taking into consideration industry standards and to commensurate with the services rendered by Mr. Harkishan Ambaram Jani, Executive Director of the Company, has the view that the present remuneration, which is being paid to him as aforementioned is not sufficient one and the same needs to be revised. Hence, the Board of Directors in its meeting held on August 28, 2024 has decided to revise the remuneration payable to the Mr. Harkishan Ambaram Jani as stated in the item no. 3 of this notice.

Accordingly, Board do hereby seek Members approval by way of Special Resolution for revision in remuneration payable to Mr. Harkishan Ambaram Jani, Executive Director of the Company as provided in the item no. 3 of the Notice for his remaining term.

The brief profile and other details of Mr. Harkishan Ambaram Jani in terms of Secretarial Standards on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI) are provided in note no. 9 of this Notice.

The performance of the Company has improved and is expected to improve further in the coming years. However, in view of adverse conditions, it incur losses due to uncontrollable reasons, resulting in inadequate profits to pay managerial remuneration. In such an event, Mr. Harkishan Ambaram Jani, may be entitled to minimum remuneration. Accordingly, the statement as required under Section II, Part II of the Schedule V to the Act with reference to Special Resolution at Item No. 3 is as follow:

## 1. General Information

### a) Nature of Industry:

The Company is engaged in the business of trading of Pharmaceutical Products.

### b) Date or expected date of commencement of commercial production:

January, 2020

### c) In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: N.A.

### d) Financial performance based on given indicators

(₹ in lakhs)

Particulars	Year Ended March 31, 2024	Year Ended March 31, 2023
Revenue from Operations	4476.70	1460.95
Profit before Tax	(2079.65)	(1223.80)
Less: Income Tax	--	--
Deferred Tax	334.13	94.76
Profit/(loss) for the Year	(1745.52)	(1129.04)

### e) Foreign Investments or collaborations, if any:

The Company has neither made any foreign investment nor entered into any foreign collaboration.

## 2. Information about the appointee

### a) Background details

The background details and profile of Mr. Harkishan Ambaram Jani stated in "Brief resume of the Director including nature of expertise in specific functional areas and Experience" in note no. 9 to this notice.

### b) Past remuneration

The remuneration of Rs. 6.80 lakhs was paid to Mr. Harkishan Ambaram Jani for the financial year 2023-24.

c) **Recognition or awards:** N.A.

d) **Job profile and his suitability**

Mr. Harkishan Ambaram Jani has done Diploma in Pharmacy in the year of 1997 from the Bhavnagar University. Mr. Harkishan's experience in pharmacy business spans over 20 years in several company including Apollo Hospitals Enterprises Limited, Gujarat and Aristo Pharmaceuticals Ltd. Occupying senior management and executive positions, his experience encompasses a broad range of pharmacy specific activities. He possesses a strong command over operational activities relating to retail pharmacy. He is also associated with the Company as an Executive Director since last 1 year and he is taking care of operations of COCO stores and overall management.

e) **Remuneration proposed**

The details of proposed remuneration to be paid to Mr. Harkishan Ambaram Jani is as below:

- a. **Remuneration:** In the scale of ₹ 12,00,000/- to ₹ 24,00,000/- per annum w.e.f. October 01, 2024 to July 31, 2028, basis annual performance evaluation by the Board (including any committee formed thereunder from time to time) to increase the same from time to time within the aforesaid range provided it remains in accordance with the limits specified in Schedule V of the Companies Act, 2013, as amended from time to time. The annual or other increments will be merit based and will take into account the Company's performance apart from individual's performance;
- b. **Sitting Fees:** NIL

f) **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person**

Taking into account the Industry in which Company Operates, Size of the Company, Experience, Skills, Expertise and responsibilities that is being handling by Mr. Harkishan Ambaram Jani, the remuneration payable is equivalent with the remuneration packages paid in the peer companies.

g) **Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any**

Apart from the remuneration paid to Mr. Harkishan Ambaram Jani for the position of Executive Director, he does not have any pecuniary relationship directly or indirectly with the Company and its managerial personnel.

3. **Other Information**

a. Reasons of loss or inadequate profits	The Company is engaged in the business of opening and operating the Company Owned Company Operated (COCO) store of Davaindia and under this initiative till March 31, 2024; the Company has already opened 253 COCO stores of Davaindia. The Company is forayed to open more COCO stores of Davaindia in foreseeable future. To open a single COCO stores a Company shall require capax of 14-18 lacs, further the newly opened COCO store will might take some time to achieve the breakeven position. Hence, for aggressive escalation of the COCO store project, to take the advantage of first movers and to manage the daily operations of the COCO stores, the Company has incurred huge working capital expenses in the project. The Company is poised that with increasing numbers of new stores and sales volume, the Company shall able to tapering the effect of expenses.
b. Steps taken or proposed to be taken for improvement	
c. Expected increase in productivity and profits in measurable terms	

Pursuant to Section 102 of the Companies Act, 2013, The Board of Directors of the Company do hereby confirm that except Mr. Harkishan Ambaram Jani; none of its Director or their immediate relatives are concerned or interested, financially or otherwise, in the aforesaid item no. 3.

The Board of Directors recommends the Special Resolution as set out in Item No. 3 in the Notice for approval of the Shareholders.

**Item No. 04:**

Members may note that your Company is unlisted material subsidiary of M/s Zota Health Care Limited ("our parent company"), accordingly as per Regulation 24(1) of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, it shall be required that at least one independent director on the board of directors of the listed entity shall be a director on the board of directors of an unlisted material subsidiary, whose income or net worth exceeded twenty percent of the consolidated income or net worth respectively, of the listed entity and its subsidiaries in the immediately preceding accounting year and as per the consolidated financial statement for the year 2023-24, the Company's income exceeded twenty percent of the consolidated income of our parent Company. Accordingly, Mr. Vitrag Sureshkumar Modi (DIN No.: 08457204) was appointed as an Additional Director to be designated as Non-Executive Independent Director of the Company by the Board of Directors of the Company in its meeting held on August 28, 2024. In terms of Section 161(1) of the Companies Act, 2013 Mr. Vitrag Sureshkumar Modi can hold office only up to the date of the ensuing Annual General Meeting.

The Board of Directors has appointed him as Non-Executive Independent Director for the term of five consecutive years starting from August 28, 2024, subject to the members' approval in ensuing general meeting. Apart from the sitting fees ₹ 5000/- for attending Board or Committee meetings, which is subject to revision from time to time as may be decided by the Board of Directors, he will not receive any remuneration. Mr. Vitrag Sureshkumar Modi is independent to the Company and possesses the required qualifications and skills.

Mr. Vitrag Sureshkumar Modi satisfies all the conditions as set out in Schedule IV to the Act, sub-section (6) of Section 149 of the Act, section 150 of the Act w.r.t. inclusion of his name in Independent Director Data Bank and passing of online proficiency self-assessment test. He has also confirmed that he is not disqualified from being appointed as Director in terms of Section 164 of the Act and has given his consent to act as Director in terms of Section 152 of the Act. Mr. Vitrag Sureshkumar Modi is not debarred from holding the office of Director by virtue of any order issued by Securities and Exchange Board of India Order or any such authority.

The brief profile and other details of Mr. Vitrag Sureshkumar Modi in terms of Secretarial Standards on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI) are provided in note no. 9 of this Notice.

In the opinion of the Board of Directors, Mr. Vitrag Sureshkumar Modi possesses the requisite integrity, expertise and experience and fulfil the criteria of Independence as specified under Section 149 of the Companies Act, 2013, as may be amended from time to time.

Pursuant to Section 102 of the Companies Act, 2013, the Board of Directors of the Company do hereby confirm that except Mr. Vitrag Sureshkumar Modi; none of its Director or their immediate relatives are concerned or interested, financially or otherwise, in the aforesaid item no. 04.

Accordingly, the Directors recommend the matter and the resolution set out under Item no. 04 for the approval of the Members by way of passing a Special Resolution.

**DAVAINDIA HEALTH MART LIMITED**

**Registered Office:** Shop No. G 44 Ayappa Ind, Zota House, Bhedwad, Choryasi, Surat– 394220, Gujarat

**CIN:** U24110GJ2020PLC111827

**Ph No.:** +91 261 2331601 **Email:** info@zotahealthcare.com

**ATTENDANCE SLIP**

Name of the member(s):	
Registered Address:	

Folio No	
No. of Shares	

*DP ID	
*Client ID	

\* Applicable to holders holding shares in demat/electronic form

I hereby record my attendance at the 5<sup>th</sup> Annual General Meeting of the Company held on **Monday, the 30<sup>th</sup> day of September, 2024** at at the Registered Office of the Company situated at Shop No. G 44 Ayappa Ind. Zota House, Bhedwad, Choryasi, Surat-394220, Gujarat at 11:00 A.M.

\_\_\_\_\_  
Shareholders Signature

**Note:**

1. Please fill this attendance slip and hand it over at the entrance of the Meeting Hall.
2. Members signature should be in accordance with the specimen signature in the Register of Members of the Company.



**DAVAINDIA HEALTH MART LIMITED****Registered Office:** Shop No. G 44 Ayappa Ind, Zota House, Bhedwad, Choryasi, Surat– 394220, Gujarat**CIN:** U24110GJ2020PLC111827**Ph No.:** +91 261 2331601 **Email:** info@zotahealthcare.com**Form MGT-11****PROXY FORM****[Pursuant to section 105(6) if the Companies Act, 2013 and rule 19(3) if the Companies (Management and Administration Rules, 2014)]**

Name of the member(s):	
Registered Address:	
E-mail ID:	
Folio No/ *Client ID:	
*DP ID:	

\*Applicable for holders holding shares in demat/ electronic mode

I/We, being the member(s) of ..... shares of the above named company, hereby appoint

1. Name:.....Address:.....  
E-mail ID: .....Signature: .....**Or failing him**
2. Name:.....Address:.....  
E-mail ID: .....Signature: ..... **Or failing him**
3. Name:.....Address:.....  
E-mail ID: .....Signature: .....

As my/our proxy to attend and vote (on a poll) for me/ us and my/our behalf at the 5<sup>th</sup> Annual General Meeting of the Company, to be held on **Monday, the 30<sup>th</sup> day of September, 2024** at 11:00 A.M. at the Registered Office of the Company situated at Shop No. G 44 Ayappa Ind. Zota House, Bhedwad, Choryasi, Surat-394220, Gujarat and at any adjournment thereof in respect of such resolutions as are indicated below:

Sr. No.	Resolution	For	Against
	<b>Ordinary Businesses:</b>		
1	To receive, consider & adopt the Audited Financial Statements of the Company for the financial year ended on March 31, 2024, together with the reports of the board of Directors and the Auditor thereon.		
2	To appoint a director in place of Mr. Viren Manukant Zota, Director (DIN: 08656333) who retires by rotation in terms of section 152(6) of the Companies Act, 2013; and being eligible offers himself to be re-appointed.		
	<b>Special Businesses:</b>		
3	To Change the terms of Appointment of Mr. Harkishan Ambaram Jani (DIN-10247676), Executive Director of the Company:		
4	To Appoint Mr. Vitrag Sureshkumar Modi (DIN-08457204) as Non-executive Independent Director of the Company:		

Shareholder's Signature

Affix Re. 1  
Revenue Stamp

---

---

**INDEPENDENT AUDITOR'S REPORT**

**TO THE MEMBERS OF DAVAINdia HEALTH MART LIMITED**

**Report on the Audit of the Financial Statements**

I have audited the accompanying financial statements of DAVAINdia HEALTH MART LIMITED (the "company"), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Cash Flows for the year ended on that date and a summary of the material accounting policies and other explanatory information (hereinafter referred to as the "financial statements").

In my opinion and to the best of my information and according to the explanations given to me, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, the loss including other comprehensive income, changes in equity and its cash flows for the year ended on that date.

**Basis for Opinion**

I conducted my audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. My responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to my audit of the financial statements under the provisions of the Act and the Rules made thereunder, and I have fulfilled my other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion on the financial statements.

**Key Audit Matters**

I have determined that there are no key audit matters to communicate in my report.

**Information Other than the Financial Statements and Auditor's Report Thereon**

The Company's Management and Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and my auditor's report thereon.

My opinion on the standalone financial statements does not cover the other information and I do not express any form of assurance conclusion thereon.

In connection with my audit of the standalone financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or my knowledge obtained during the course of my audit or otherwise appears to be materially misstated.

If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact. I have nothing to report in this regard.

**Management's Responsibility for the Financial Statements**

The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Statements**

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, I am also responsible for expressing my opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements:**

- 1 As required by section 143(3) of the Act, I report that :
  - a I have sought and obtained all the information and explanations, which to the best of my knowledge and belief were necessary for the purpose of my audit;
  - b In my opinion proper books of accounts as required by Law have been kept by the company, so far as it appears from my examination of the books;
  - c The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Cash Flow Statement and the Statement of Changes in Equity dealt with by this report are in agreement with the books of account.

- d In my opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act;
- e On the basis of the written representations received from the directors as on March 31, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- f With respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to my separate Report in "Annexure A". My report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g In my opinion and to the best of my information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 read with Schedule V to the Act;
- h With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in my opinion and to the best of my knowledge and belief and according to the information and explanations given to me:
- (i) The Company does not have any pending litigations which would impact its financial position.
- (ii) The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
- (iii) There were no amounts which required to be transferred, to the Investor Education and Protection Fund by the Company.
- (iv) (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- (v) The company has neither paid nor declared any dividend during the year.
- (vi) Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with. As provision to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2024.
- 2 As required by the Companies (Auditor's Report) Order, 2020, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act (the "Order") and according to the information and explanations given to me, I enclose in the "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

**For Poonam Murarka And Associates**  
**Chartered Accountants**  
**Firm No. 153909W**

**Date: 20-05-2024**  
**Place : Surat**

**Poonam Murarka**  
**Proprietor**  
**M. No. 188906**  
**UDIN: 24188906BKEIYB5972**

---

---

**ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT**

**(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of my report to the Members of Davaindia Health Mart Limited)**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

I have audited the internal financial controls with reference to standalone financial statements of Davaindia Health Mart Limited ("the Company") as of 31st March 2024 in conjunction with my audit of the financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's Management and Board of Directors of the Company are responsible for establishing and maintaining internal financial controls based on the internal financial control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors' Responsibility**

My responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on my audit. I conducted my audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

My audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. My audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion on the Company's internal financial controls system with reference to financial statements.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that :

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In my opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at 31st March 2024, based on the internal financial control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Poonam Murarka And Associates**  
**Chartered Accountants**  
**Firm No. 153909W**

**Poonam Murarka**  
**Proprietor**  
**M. No. 188906**  
**UDIN: 24188906BKEIYB5972**

**Date: 20-05-2024**  
**Place : Surat**

---

---

**ANNEXURE "B" TO THE INDEPENDENT AUDITOR'S REPORT**

**(Referred to in paragraph 2, under 'Report on Other Legal and Regulatory Requirements' section of my Report to the Members of Davaindia Health Mart Limited of even date)**

- (i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:
  - a
    - (i) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment and relevant details of right-of-use assets.
    - (ii) the company does not have any intangible assets for the current period.
  - b According to the information and explanations given to me, all property, plant & equipment have been physically verified by the management during the period at reasonable intervals. As explained to me, no material discrepancies were noticed as compared to the books records, on such physical verification.
  - c According to the information and explanations given to me, the title deeds of immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) included in property, plant and equipment are held in the name of the Company.
  - d According to the information and explanations given to me and on the basis of examination of the records of the Company, the Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) during the year.
  - e According to the information and explanations given to me and on the basis of examination of the records of the Company, there are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii)
  - (a) The inventory has been physically verified by the management during the year. In my opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.
  - (b) The Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
- (iii) According to the information and explanations given to me and on the basis of my examination of the records of the Company, the Company has not made any investments, provided guarantee or security or granted any advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year. Hence, the requirements under paragraph 3(iii) of the Order are not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, the Company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provisions of section 185 of the Act and the Company has not made investments through more than two layers of investment companies in accordance with the provisions of section 186 of the Act. Accordingly, provisions stated in paragraph 3(iv) of the Order are not applicable to the Company.

- (v) According to the information and explanations given to me, the Company has not accepted deposits from the public and the other security deposits accepted are not considered as deposits as per section 73 to 76. Therefore, the provisions of the clause 3(v) of the Order are not applicable to the Company.
- (vi) The provisions of sub-section (1) of section 148 of the Act are not applicable to the Company as the Central Government of India has not specified the maintenance of cost records for any of the products of the Company. Accordingly, the provisions stated in paragraph 3 (vi) of the Order are not applicable to the Company.
- (vii) According to the information and explanations given to me, in respect of statutory dues :
  - a According to the information and explanations given to me and according to the records, the Company has generally been regular in depositing undisputed statutory dues with appropriate authorities during the year.  
  
There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they became payable.
  - b According to the information and explanations given to me and the statutory examination of the records, there are no disputed dues which have not been deposited on account of Disputed matters pending before the appellate authorities.
- (viii) According to the information and explanations given to me and on the basis of examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.
- (ix) The Company has not taken any loans or borrowings from financial institutions, banks and government or has not issued any debentures. Hence reporting under clause 3(ix) of the Order is not applicable to the Company.
- (x)
  - a The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3(x)(a) of the Order is not applicable to the Company.
  - b During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause 3(x)(b) of the Order is not applicable to the Company.
- (xi)
  - a To the best of my knowledge and according to the information and explanations given to me, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
  - b According to the information and explanations given to me, no report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
  - c As represented to me by the management, there are no whistle-blower complaints received by the Company during the year. Accordingly, the provisions stated in paragraph (xi)(c) of the Order is not applicable to company.
- (xii) The Company is not a Nidhi Company and hence reporting under clause 3(xii) (a) to (c) of the Order is not applicable to the Company and hence not commented upon.
- (xiii) In my opinion and according to the information and explanations given to me, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and the details have been disclosed in the notes to the standalone financial statements, as required by the applicable accounting standards.
- (xiv)
  - a In our opinion and based on our examination, the Company does not require to comply with provision of section 138 of the Act. Hence, the provisions stated in paragraph 3(xiv) (a) to (b) of the Order are not applicable to the Company.
  - b The company did not have an internal audit system for the period under audit.



- (xv) In my opinion and according to the information and explanations given to me, during the year the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of Companies Act, 2013.
- (xvi) a The Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph clause 3 (xvi)(a) of the Order are not applicable to the Company.
- b The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, the requirement to report on clause (xvi)(b) of the Order is not applicable to the Company.
- c The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) (c) of the Order is not applicable to the Company
- (xvii) Based on the overall review of the financial statements, the Company has incurred cash losses in the current financial year and in the immediately preceding financial year. The details of the same are as follows:

March 31, 2024	March 31, 2023
₹ 371.87 lakhs	₹ 270.08 lakhs

- (xviii) There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
- (xix) On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on my examination of the evidence supporting the assumptions, nothing has come to my attention, which causes me to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. I, however, state that this is not an assurance as to the future viability of the Company. I further state that my reporting is based on the facts up to the date of the audit report and I neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) According to the information and explanations given to us, the provisions of section 135 of the Act are not applicable to the Company. Hence, the provisions of paragraph (xx)(a) to (b) of the Order are not applicable to the Company.

**For Poonam Murarka And Associates**  
**Chartered Accountants**  
**Firm No. 153909W**

**Poonam Murarka**  
**Proprietor**

**Date: 20-05-2024**  
**Place : Surat**

**M. No. 188906**  
**UDIN: 24188906BKEIYB5972**

**DAVAINDIA HEALTH MART LIMITED**  
**Balance Sheet as at 31st March, 2024**

(All Amounts in ₹ Lakhs)

Particulars		Note No.	As at 31st March, 2024	As at 31st March, 2023
(1)	<b>ASSETS</b>			
	<b>Non-Current Assets</b>			
	Property, plant and equipment	3(a)	1568.99	756.88
	Right-of-use assets	3(b)	7506.83	4306.82
	Financial Assets			
	(i) Investments			
	(iii) Loans			
	Deferred Tax Assets (net)	4	437.66	103.53
	Other Non-current assets			
	<b>Total Non-Current assets</b>		<b>9513.47</b>	<b>5167.23</b>
(2)	<b>Current Assets</b>			
	Inventories	5	1522.74	720.37
	Financial Assets			
	(i) Trade Receivables	6	16.48	5.01
	(ii) Cash and Cash Equivalents	7	67.11	8.45
	(iii) Bank balance other than (ii) above	8	12.20	15.08
	(iv) Loans	9	781.08	291.08
	Other Current Assets	10	1062.78	413.99
	<b>Total Current assets</b>		<b>3462.40</b>	<b>1453.98</b>
	<b>Total Assets</b>		<b>12975.87</b>	<b>6621.21</b>
(1)	<b>EQUITY AND LIABILITIES</b>			
	<b>Equity</b>			
	(i) Equity Share capital	11	200.00	200.00
	(ii) Other Equity	12	(3027.14)	(1285.20)
	<b>Total Equity</b>		<b>(2827.14)</b>	<b>(1085.20)</b>
	<b>Liabilities</b>			
	<b>Non-Current Liabilities</b>			
	<b>Financial Liabilities</b>			
	(i) Borrowings	13	2064.04	1256.28
	(ii) Lease liabilities	14	6316.42	3626.31
(2)	<b>Provisions</b>	15	32.54	3.81
	<b>Total non-current liabilities</b>		<b>8413.00</b>	<b>4886.41</b>
	<b>Current liabilities</b>			
	<b>Financial Liabilities</b>			
	(i) Borrowings			
	(ii) Lease liabilities	14	1744.37	885.87
	(iii) Trade payables			
	- Total outstanding dues of micro enterprises and small enterprises			
	- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	16	4939.80	1742.32
	<b>Other Current liabilities</b>	17	422.04	165.32
(2)	<b>Provisions</b>	18	283.80	26.50
	<b>Total current liabilities</b>		<b>7390.01</b>	<b>2820.01</b>
	<b>Total Liabilities</b>		<b>15803.01</b>	<b>7706.41</b>
	<b>Total Equity and Liabilities</b>		<b>12975.87</b>	<b>6621.21</b>

See accompanying notes to the financial statements  
For and on behalf of the Board

For Poonam Murarka And Associates  
Chartered Accountants  
Firm No. 153909W

(Director) Himanshu M. Zota  
(Din : 01097722)  
34, Ichhanath Umra,  
Surat.,

(Director) Moxesh K. Zota  
(Din : 07625219)  
8D, Lal Bunglow, Athwalines,  
Surat.,

Poonam Murarka  
Proprietor  
M. No. 188906  
UDIN: 24188906BKEIYB5972

Date: 20-05-2024  
Place : Surat

**DAVAINDIA HEALTH MART LIMITED**  
**Statement of Profit & Loss for the year ended 31st March, 2024**

(All Amounts are ₹ in Lakhs except per share data)

Particulars		Note No.	Year Ended 31st March, 2024	Year Ended 31st March, 2023
I.	Revenue from Operations	19	4476.70	1460.95
II.	Other Income	20	1.39	0.65
III.	<b>Total Income</b>		4478.09	1461.60
IV.	<b>Expenses:</b>			
	Purchases of Stock-in-Trade		3086.35	1301.86
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	21	(802.37)	(606.12)
	Employee Benefit Expenses	22	1047.69	146.29
	Finance Costs	24	532.98	310.93
	Depreciation and amortization expense	23	1707.78	953.72
	Other Expenses	25	985.31	578.72
V.	<b>Total Expenses</b>		6557.74	2685.40
VI.	Profit/(loss) before exceptional items and tax (III-V)		(2079.65)	(1223.80)
	Exceptional items			
VII.	Profit/(loss) before tax		(2079.65)	(1223.80)
VIII.	Tax Expense:			
	(1) Current tax		-	-
	(2) Deferred Tax		334.13	94.76
	Total Tax Expense		334.13	94.76
IX.	Profit/ (Loss) for the Year		(1745.52)	(1129.04)
	<b>Other Comprehensive Income</b>			
	A (i) Items that will not be reclassified to Statement of profit and loss		4.78	1.06
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss		(1.19)	(0.26)
	B (i) Items that will be reclassified to Statement of profit and loss		-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss		-	-
	Total other comprehensive income for the year, net of tax		3.58	0.79
	<b>Total comprehensive income for the year</b>		(1741.94)	(1128.25)
	Earnings Per Equity Share			
	(1) Basic		-87.28	-56.45
	(2) Diluted		-87.28	-56.45

**Significant Accounting Policies**

See accompanying notes to the financial statements

For Poonam Murarka And Associates

Chartered Accountants

Firm No. 153909W

For and on behalf of the Board

(Director)

Himanshu M. Zota

(Din : 01097722)

34, Ichhanath Umra,  
Surat.,

Date: 20-05-2024

Place : Surat

(Director)

Moxesh K. Zota

(Din : 07625219)

8D, Lal Bungalow, Athwalines,  
Surat.,

Poonam Murarka

Proprietor

M. No. 188906

UDIN: 24188906BKEIYB5972

**DAVAINDIA HEALTH MART LIMITED****Statement of changes in equity for the year ended 31st March, 2024**

(All Amounts in ₹ Lakhs)

**A. Equity share capital**

<b>Particulars</b>	<b>Balance at the beginning of the reporting year</b>	<b>Changes in equity share capital during the year</b>	<b>Balance at the end of the reporting year</b>
For the year ended 31st March, 2024	200.00	-	200.00
For the year ended 31st March, 2023	200.00	-	200.00

**B. Other equity**

<b>Particulars</b>	<b>Attributable to owners of the Company</b>	
	<b>Retained Earnings</b>	<b>Total</b>
<b>As at 31.03.2022</b>	<b>(156.96)</b>	<b>(156.96)</b>
Profit/(loss) for the year	(1129.04)	(1129.04)
Other comprehensive income	0.79	0.79
Total comprehensive income for the year	(1128.25)	(1128.25)
<b>As at 31.03.2023</b>	<b>(1285.20)</b>	<b>(1285.20)</b>
Profit/(loss) for the year	(1745.52)	(1745.52)
Other comprehensive income	3.58	3.58
Total comprehensive income for the year	(1741.94)	(1741.94)
<b>As at 31.03.2024</b>	<b>(3027.14)</b>	<b>(3027.14)</b>

The accompanying notes are an integral part of the financial statements.

See accompanying notes to the financial statements  
For and on behalf of the Board

For Poonam Murarka And Associates  
Chartered Accountants  
Firm No. 153909W

(Director)  
Himanshu M. Zota  
(Din : 01097722)  
34, Ichhanath Umra,  
Surat.,

(Director)  
Moxesh K. Zota  
(Din : 07625219)  
8D, Lal Bunglow, Athwalines,  
Surat.,

Poonam Murarka  
Proprietor  
M. No. 188906

Date: 20-05-2024  
Place : Surat

**DAVAINDIA HEALTH MART LIMITED**  
**Statement of Cash Flows for the year ended March 31, 2024**

(All Amounts in ₹ Lakhs)

Particulars	Year Ended 31.03.2024	Year Ended 31.03.2023
<b>Cash flow from operating activities</b>		
Profit/(loss) before tax	(2079.65)	(1223.80)
Adjustment for :		
Depreciation and amortization expense	1707.78	953.72
Finance Costs	506.74	306.90
<b>Operating profit/(loss) before working capital changes</b>	<b>134.87</b>	<b>36.82</b>
Adjusted for:		
Inventories	(802.37)	(606.12)
(Increase)/decrease in Trade Receivables	(11.47)	(4.60)
(Increase)/decrease in Other Current Assets	(648.79)	(274.80)
Increase in Trade payables	3197.48	1508.81
Increase/(decrease) in Other Current liabilities	256.72	145.78
Increase in Provisions	290.80	22.99
<b>Changes in Working Capital</b>	<b>2282.36</b>	<b>792.05</b>
<b>Cash generated from operations</b>	<b>2417.23</b>	<b>828.87</b>
Direct Taxes Paid	(1.19)	(0.26)
<b>Net Cash flow from/ (used in) operating activities (A)</b>	<b>2416.04</b>	<b>828.61</b>
<b>Cash flow from Investing activities</b>		
Purchase of property, plant and equipment	(1140.41)	(749.15)
<b>Net cash flow from / (used in) investing activities (B)</b>	<b>(1140.41)</b>	<b>(749.15)</b>
<b>Cash flow from financing activities</b>		
Principal payment of lease liability	(1030.87)	(591.38)
Interest payment of lease liability	(415.77)	(245.99)
Finance Costs	(90.97)	(60.91)
Borrowings - Non-Current	807.76	1004.78
Loans	(490.00)	(171.99)
<b>Net cash flow from / (used in) financing activities (C)</b>	<b>(1219.85)</b>	<b>(65.49)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>55.78</b>	<b>13.96</b>
Cash and Cash Equivalents at the beginning of the year	23.53	9.57
<b>Cash and Cash Equivalents at the end of the year</b>	<b>79.31</b>	<b>23.53</b>

The accompanying notes are an integral part of the financial statements.

For and on behalf of the Board

For Poonam Murarka And Associates  
Chartered Accountants  
Firm No. 153909W

(Director)  
Himanshu M. Zota  
(Din : 01097722)  
34, Ichhanath Umra,  
Surat.,

(Director)  
Moxesh K. Zota  
(Din : 07625219)  
8D, Lal Bungalow, Athwalines,  
Surat.,

Poonam Murarka  
Proprietor  
M. No. 188906

Date: 20-05-2024

Place : Surat

**NOTE - 01****COMPANY OVERVIEW:**

Davaindia Health Mart Limited is a public limited company incorporated and domiciled in India. The Company is wholly owned subsidiary company of Zota Health Care Ltd. The Company is established as a drug manufacturing, development, and marketing company. The Company is engaged in the business of running the "Company Owned Company Operated (COCO) retail pharmacy stores of "Davaindia" (endeavor of Company's Parent Company, Zota Health Care Limited) and offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products.

The Company has its registered office Shop No. G 44 Ayappa Ind, Zota House, Bhedwad, Choryasi, Surat - 394220 Gujarat, India.

The financial statements are approved for issue by the Board of Directors of the Company in its meeting held on May 20, 2024.

**NOTE - 02****1. MATERIAL ACCOUNTING POLICIES**

The following note provides list of the material accounting policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented unless otherwise stated.

**1.1 Basis of Preparation of Financial Statements:**

These financial statements are prepared in accordance with Indian Accounting Standard (Ind AS), under the historical cost convention on the accrual basis. The Ind AS are prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter.

The Company's Financial Statements are presented in Indian rupees and all values are rounded to the nearest Lakh (₹ 00,000), except when otherwise indicated.

**1.2 Use of estimates and judgments**

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Any change in these estimates and assumptions will generally be reflected in the financial statements in current period or prospectively, unless they are required to be treated retrospectively under relevant accounting standards.

**1.3 Summary of material accounting policies****i. Current and non-current classification**

The assets and liabilities reported in the balance sheet are classified on a "current/non-current basis".

An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realized within twelve months after the reporting period, or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

### **Operating Cycle**

Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

## **ii. Segment Information**

Operating segments are defined as components of an enterprise for which discrete financial information is available that is evaluated regularly by the chief operating decision maker. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, is responsible for allocating resources and assessing performance of the operating segments and makes strategic decisions.

## **iii. Revenue recognition**

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Arrangements with customers for sale of goods are on a fixed-price.

The company accounts for volume discounts and pricing incentives to customers as a reduction of revenue based on the ratable allocation of the discounts/incentives to each of the underlying performance obligation that corresponds to the progress by the customer towards earning the discount/incentive.

If it is probable that the criteria for the discount will not be met, or if the amount thereof cannot be estimated reliably, then discount is not recognized until the payment is probable and the amount can be estimated reliably.

### **Interest income**

For all financial instruments measured at amortized cost, interest income is recorded using the effective interest rate, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial instrument. Interest income is included in 'Other Income' in the Statement of Profit and Loss.

**iv. Income tax**

Income tax expense comprises of current tax and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent that it relates to items recognized directly in equity/OCI, in which case it is recognized in other comprehensive income. The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities attributable to temporary differences.

**Current income tax**

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period. The provision for current tax is made at the rate of tax as applicable for the income of the previous year as defined under the Income tax Act, 1961. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provision where appropriate on the basis of amounts expected to be paid to the tax authorities.

Current tax assets and current tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

**Deferred tax**

Deferred tax is recognized using the Balance Sheet approach on temporary differences at the reporting date arising between the tax bases of assets and liabilities and their carrying amounts for the financial reporting purpose at the reporting date.

Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carry-forwards and unused tax credits could be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.

Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured based on the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

Current and deferred tax is recognized in Statement of Profit and Loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.

**v. Cash and cash equivalents**

The Company considers all highly liquid financial instruments which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.



**vi. Financial instruments:**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument.

**Financial assets:****Classification**

The Company classifies its financial assets in the following measurement categories:

-those to be measured subsequently at fair value (either through other comprehensive income, or through the Statement of Profit and Loss), and

-those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

**Initial recognition and measurement**

Financial assets are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through Profit and Loss, transaction costs that are attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through Profit and Loss are expensed in the Statement of Profit and Loss.

**Subsequent measurement**

After initial recognition, financial assets are measured at:

fair value (either through other comprehensive income or through Profit and Loss), or amortized cost.

**vii. Financial liabilities:****Initial recognition and measurement**

Financial liabilities are initially measured at its fair value plus or minus, in the case of a financial liability not at FVTPL, transaction costs that are directly attributable to the issue/origination of the financial liability.

**Subsequent measurement**

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in statement of profit and loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in Statement of profit and loss. Any gain or loss on de-recognition is also recognized in statement of Profit and Loss.

**De-recognition**

A financial liability is derecognized when the obligation specified in the contract is discharged, cancelled or expires.

**viii. Property, Plant and Equipment (PPE)**

Items of Property, plant and equipment acquired or constructed are initially recognized at historical cost net of recoverable taxes, duties, trade discounts and rebates, less accumulated depreciation and impairment loss, if any. The historical cost of Property, plant and equipment comprises of its purchase price, borrowing costs and adjustment arising for exchange rate variations attributable to the assets, including any cost directly attributable to bringing the assets to their working condition for their intended use.

Capital Work-in-Progress represents Property, plant and equipment that are not ready for their intended use as at the reporting date.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

The Company identifies and determines cost of each component/part of the plant and equipment separately, if the component/part has a cost which is significant to the total cost of the plant and equipment and has useful lives that is materially different from that of the remaining plant and equipment.

The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Statement of Profit and Loss during the year in which they are incurred.

Gains and losses arising from de-recognition of PPE are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized.

Depreciation methods, estimated useful lives and residual values:

Depreciation is provided, pro-rata for the period in use, on the written down value method based on the respective estimate of useful lives. Estimated useful lives of assets are determined based on technical parameters/assessments.

The Management believes that useful lives currently used, which is prescribed under Part C of Schedule II to the Companies Act, 2013, fairly reflects its estimate of the useful lives and residual values of PPE.

Estimated useful lives, residual values and depreciation methods are reviewed annually, taking into account commercial and technological obsolescence as well as normal wear and tear and adjusted prospectively, if appropriate.

Advances paid towards the acquisition of PPE outstanding at each Balance Sheet date is classified as capital advances under 'Other non-current assets' and cost of assets not put to use before such date are disclosed under 'Capital work-in-progress'.

**ix. Intangible assets**

Intangible Assets are stated at cost of acquisition net of recoverable taxes, trade discount and rebates less accumulated amortization/depletion and impairment loss, if any. Such cost includes purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the entity and the cost can be measured reliably.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized.

**x. Provisions and contingent liabilities**

**Provisions**

Provisions are recognized when there is a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

**Contingencies**

Contingent liabilities are disclosed in the Notes to the financial statements. Contingent liabilities are disclosed for

- when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company, or
- a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made.

**xi. Earnings per Share**

Basic earnings per share is calculated by dividing the net profit after tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for

events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

## xii. Leases

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

- i.) Right-to-use assets- The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets, as follows:

ROU	Useful life
Shop Premises	5 Years

If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. Refer to the accounting policies in section Impairment of nonfinancial assets.

- ii.) Lease Liabilities- At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Variable lease payments that do not depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

## xiii. Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates

the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or Cash Generating Unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

Impairment losses of continuing operations are recognised in the statement of profit and loss.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount.

A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss. After impairment, amortisation is provided on the revised carrying amount of the asset over its remaining useful life.

#### **xiv. Inventories**

All the Inventory are Valued at the cost or net realizable value whichever is low.

Total cost includes cost of purchases and other costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

#### **xv. Employee benefits**

The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognized immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Past service costs are recognised in profit or loss on the earlier of:

- The date of the plan amendment or curtailment, and
- The date that the Company recognises related restructuring costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:

- Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- Net interest expense or income

#### Short term benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short term employee benefits. Benefits such as salaries, wages, bonus, short term compensated absences and the expected cost of ex-gratia is recognized in the period in which the employee renders the related service.

#### xvi. Cash flow statement

Cash flows are reported using the Indirect Method, as set out in Ind-AS 7 'Statement of Cash Flow', whereby profit for the year is adjusted for the effects of transaction of non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

2. **Recent pronouncements** - The Ministry of Corporate Affairs ("MCA") notifies new standards or amendment to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

#### Signatures to Notes 1 to 27

For and on behalf of the Board

For Poonam Murarka and Associates  
Chartered Accountants

Himanshu M. Zota  
(Director)  
(Din : 01097722)  
34, Ichhanath Umra,  
Surat.,

Moxesh K. Zota  
(Director)  
(Din : 07625219)  
8D, Lal Bunglow,  
Athwalines, Surat.,

Poonam Murarka  
Proprietor  
M. No. 188906  
Firm No. 153909W

Date: 20-05-2024

Place : Surat

**DAVAINDIA HEALTH MART LIMITED**

Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024

**3(a) Property, plant and equipment**

(₹ in Lakhs)

<b>Cost</b>	<b>Computers</b>	<b>Office Equipments</b>	<b>Furniture and Fixtures</b>	<b>Total Amount</b>
<b>As at March 31, 2022</b>	<b>9.93</b>	<b>25.51</b>	<b>172.18</b>	<b>207.62</b>
Additions	82.59	105.73	560.83	749.15
Disposals	-	-	-	-
Adjustments	-	-	-	-
<b>As at Mar 31, 2023</b>	<b>92.53</b>	<b>131.24</b>	<b>733.01</b>	<b>956.78</b>
Additions	135.55	181.98	822.88	1140.41
Disposals	-	-	-	-
Adjustments	-	-	-	-
<b>As at March 31, 2024</b>	<b>228.07</b>	<b>313.22</b>	<b>1555.89</b>	<b>2097.18</b>
<b>Depreciation and amortisation</b>	<b>Computers</b>	<b>Office Equipments</b>	<b>Furniture and Fixtures</b>	<b>Total Amount</b>
<b>As at March 31, 2022</b>	<b>0.95</b>	<b>3.90</b>	<b>17.57</b>	<b>22.42</b>
Depreciation charge for the year	32.23	32.22	113.03	177.48
Disposals	-	-	-	-
Adjustments	-	-	-	-
<b>As at March 31, 2023</b>	<b>33.18</b>	<b>36.13</b>	<b>130.59</b>	<b>199.90</b>
Depreciation charge for the year	53.18	62.63	212.50	328.30
Disposals	-	-	-	-
Adjustments	-	-	-	-
<b>As at March 31, 2024</b>	<b>86.35</b>	<b>98.75</b>	<b>343.09</b>	<b>528.20</b>
<b>Net Block</b>	<b>Computers</b>	<b>Office Equipments</b>	<b>Furniture and Fixtures</b>	<b>Total Amount</b>
<b>As at March 31, 2024</b>	<b>141.72</b>	<b>214.47</b>	<b>1212.80</b>	<b>1568.99</b>
<b>As at March 31, 2023</b>	<b>59.35</b>	<b>95.12</b>	<b>602.41</b>	<b>756.88</b>

## DAVAINDIA HEALTH MART LIMITED

Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024

### 3(b) Right-of-use assets

As lessee

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company has entered into operating leases of office premises with no restrictions and are renewable with mutual consent after 5 years. The escalation rates range from 5% per annum as per the terms of the lease agreement. There are no sub-leases.

(₹ in Lakhs)

Set out below are the carrying amounts of right-of-use assets recognised and the movements during the year:

Particulars	31-03-2024	31-03-2023
Opening balance	4306.82	1469.56
Additions	4579.48	3613.50
Amortization	(1379.48)	(776.24)
Closing balance	7506.83	4306.82

Set out below are the carrying amounts of lease liabilities and the movements during the year:

Particulars	31-03-2024	31-03-2023
Opening balance	4512.18	1490.06
Additions	4579.48	3613.50
Finance cost accrued during the period	415.77	245.99
Deletions	-	-
Payment of lease liabilities	(1446.64)	(837.36)
Closing balance	8060.79	4512.18

The following are the amounts recognised in statement of profit and loss:

Particulars	31-03-2024	31-03-2023
Amortization of Right to use asset	1379.48	776.24
Interest on lease liabilities	415.77	245.99

Lease contracts entered by the Company pertains for buildings taken on lease to conduct its business in the ordinary course. The Company does not have any lease restrictions and commitment towards variable rent as per the contract.



**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**4 Deferred Tax Liability / (Asset)**

<b>Particulars</b>	<b>31st March, 2024 ₹ in Lakhs</b>	<b>31st March, 2023 ₹ in Lakhs</b>
<b>Deferred Tax Liabilities</b>		
Property, plant and equipments, Intangible Assets	(52.78)	(21.47)
Right-of-use assets	1889.32	1083.41
Sub Total (a)	1836.53	1061.94
<b>Deferred Tax Assets</b>		
Items allowable for tax purpose on payments/adjustment	(245.45)	(30.37)
Lease Liabilities	(2028.74)	(1135.10)
Sub Total (b)	(2274.19)	(1165.47)
<b>Total (a+b)</b>	<b>(437.66)</b>	<b>(103.53)</b>
<b>Recognised in Statement of Profit &amp; Loss for the year</b>	<b>(334.13)</b>	<b>(94.76)</b>

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

Note No.	PARTICULARS	As at 31.03.2024 Amount ₹ in lakhs	As at 31.03.2023 Amount ₹ in lakhs
5	<b>Inventories</b> Stock-in-Trade (in respect of goods acquired for trading)	1522.74	720.37
	<b>Total</b>	<b>1522.74</b>	<b>720.37</b>
	<b>Mode of Valuation.</b> Stock in Trade (in respect of goods acquired for trading): Valued at Cost .		
6	<b>Trade Receivables</b> (Unsecured and Considered Good) Trade Receivables	16.48	5.01
	<b>Total</b>	<b>16.48</b>	<b>5.01</b>
7	<b>Cash and Cash Equivalents</b> Cash on Hand	67.11	8.45
	<b>Total</b>	<b>67.11</b>	<b>8.45</b>
8	<b>Bank balance other than cash and cash equivalents</b> Balance with Bank	12.20	15.08
	<b>Total</b>	<b>12.20</b>	<b>15.08</b>
9	<b>Loans</b> (Unsecured and Considered Good) <b>Others</b>	781.08	291.08
	<b>Total</b>	<b>781.08</b>	<b>291.08</b>
10	<b>Other Current Assets</b> Balances with Govt. Authorities Others	395.49 667.30	234.58 179.41
	<b>Total</b>	<b>1062.78</b>	<b>413.99</b>
11	<b>Equity Share Capital</b> <b>Share Capital :</b> <b>Authorised Share Capital</b> 2500000 Equity Shares of Rs. 10/- each (Pre. Yr. 250000 Equity Shares of Rs. 10/- each )	250.00	250.00
	<b>Issued, Subscribed and Paid up</b> 2000000 Equity Shares of Rs. 10/- each (Pre. Yr. 100000 Equity Shares of Rs. 10/- each fully paid-up)	200.00	200.00
	<b>Total</b>	<b>200.00</b>	<b>200.00</b>
A.	<b>Reconciliation of the shares outstanding at the beginning and at the end of the reporting year:</b>		
	<b>Authorised Shares</b>	<b>No. of Shares 31st March, 2024</b>	<b>No. of Shares 31st March, 2023</b>
	Previous Year	2,50,000	2,50,000
	Increase during the year	-	-
	Current Year	2,50,000	2,50,000
	<b>Issued, Subscribed and fully paid Equity shares</b>	<b>No. of Shares 31st March, 2024</b>	<b>No. of Shares 31st March, 2023</b>
	At the beginning of the year	20,00,000	20,00,000
	Add : Addition during the year	-	-
	Outstanding at the end of the year	20,00,000	20,00,000
B.	<b>Details of shareholders holding more than 5% shares in the Company :</b>		
	<b>Name</b>	<b>No. of Shares with Ratio 31st March, 2024 No. of Share %</b>	<b>No. of Shares with Ratio 31st March, 2023 No. of Share %</b>
	Zota Health Care Limited	1999994 99.99	1999994 99.99

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

Note No.	PARTICULARS	As at 31.03.2024 Amount ₹ in lakhs	As at 31.03.2023 Amount ₹ in lakhs
<b>D.</b>	<b>Terms/rights attached to equity shares</b>		
	The Company has one class of equity shares having par value of ₹ 10/- per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.		
<b>E.</b>	<b>Equity shares movement during 5 years preceding March 31, 2024</b>		
	<u>Equity shares issued as bonus</u> The Company has not issued any bonus shares.		
	<u>Equity shares issued</u> The company has issued 19,00,000 equity shares at the rate of 10 per equity shares on right basis to the promoter group category allotted on 24/08/2021.		
<b>F.</b>	No shares were bought back in last 5 years.		
<b>12</b>	<b>Other Equity</b>		
	<b>a. Retained Earnings</b>		
	Opening balance	(1285.20)	(156.96)
	Profit for the year	(1745.52)	(1129.04)
	<b>b. Other comprehensive income of the year</b>	3.58	0.79
	<b>Closing Balance</b>	<b>(3027.14)</b>	<b>(1285.20)</b>
	Nature and purpose of reserves		
	<b>Retained earnings</b> Retained earnings comprises of prior year's undistributed earnings after taxes along with current year profit.		
<b>13</b>	<b>Borrowings - Non-Current</b>		
	Unsecured-At Amortised Cost		
	Loan from Zota Health Care Limited	2064.04	1256.28
	<b>Total</b>	<b>2064.04</b>	<b>1256.28</b>
<b>14</b>	<b>Lease liabilities</b>		
	Non-current Lease obligations	6316.42	3626.31
	Current Lease obligations	1744.37	885.87
	<b>Total</b>	<b>8060.79</b>	<b>4512.17</b>
<b>15</b>	<b>Provisions -Non-Current</b>		
	Gratuity Payable	32.54	3.81
	<b>Total</b>	<b>32.54</b>	<b>3.81</b>
<b>16</b>	<b>Trade payables</b>		
	Outstanding dues of micro and small enterprises	-	-
	Outstanding dues of creditors other than micro enterprises and small enterprises	4939.80	1742.32
	<b>Total</b>	<b>4939.80</b>	<b>1742.32</b>
	ageing		
<b>17</b>	<b>Other Current Liabilities</b>		
	Statutory Liabilities	30.65	28.16
	Others	391.39	137.17
	<b>Total</b>	<b>422.04</b>	<b>165.32</b>

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

<b>Note No.</b>	<b>PARTICULARS</b>	<b>As at 31.03.2024</b> Amount ₹ in lakhs	<b>As at 31.03.2023</b> Amount ₹ in lakhs
<b>18</b>	<b>Provisions - Current</b>		
	Provision for Employee Benefits	259.51	26.24
	Others	24.29	0.26
	<b>Total</b>	<b>283.80</b>	<b>26.50</b>

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**C. Disclosure of Shareholding of Promoters and Promoters group**

Disclosure of shareholding of promoters and promoters group as at March 31, 2024 is as follows:

Promoter name	Shares held by promoters				% Change during the year
	As at March 31, 2024		As at March 31, 2023		
	No. of shares	% of total shares	No. of shares	% of total shares	
ZOTA HEALTH CARE LIMITED	1999994	100.00%	19,99,994	100.00%	-
KAMLESH RAJNIKANT ZOTA	1	0.00%	1	0.00%	-
KETANKUMAR CHANDULAL ZOTA	1	0.00%	1	0.00%	-
MANUKANT CHANDULAL ZOTA	1	0.00%	1	0.00%	-
MOXESH KETANBHAI ZOTA	1	0.00%	1	0.00%	-
MUKTILAL CHANDULAL ZOTA	1	0.00%	1	0.00%	-
VIREN MANUKANT ZOTA	1	0.00%	1	0.00%	-

Disclosure of shareholding of promoters and promoters group as at March 31, 2023 is as follows:

Promoter name	Shares held by promoters				% Change during the year
	As at March 31, 2023		As at March 31, 2022		
	No. of shares	% of total shares	No. of shares	% of total shares	
ZOTA HEALTH CARE LIMITED	19,99,994	100.00%	19,99,994	100.00%	-
KAMLESH RAJNIKANT ZOTA	1	0.00%	1	0.00%	-
KETANKUMAR CHANDULAL ZOTA	1	0.00%	1	0.00%	-
MANUKANT CHANDULAL ZOTA	1	0.00%	1	0.00%	-
MOXESH KETANBHAI ZOTA	1	0.00%	1	0.00%	-
MUKTILAL CHANDULAL ZOTA	1	0.00%	1	0.00%	-
VIREN MANUKANT ZOTA	1	0.00%	1	0.00%	-

**DAVAINDIA HEALTH MART LIMITED**

Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024

Note No.	PARTICULARS	As at 31.03.2024 Amount ₹ in lakhs	As at 31.03.2023 Amount ₹ in lakhs
<b>D.</b>	<b>Terms/rights attached to equity shares</b>		
	The Company has one class of equity shares having par value of ₹ 10/- per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.		
<b>E.</b>	<b>Equity shares movement during 5 years preceding March 31, 2024</b>		
	<u>Equity shares issued as bonus</u>		
	The Company has not issued any bonus shares.		
	<u>Equity shares issued</u>		
	The company has issued 19,00,000 equity shares at the rate of 10 per equity shares on right basis to the promoter group category allotted on 24/08/2021.		
<b>F.</b>	No shares were bought back in last 5 years.		
<b>12</b>	<b>Other Equity</b>		
	<b>a. Retained Earnings</b>		
	Opening balance	(1285.20)	(156.96)
	Profit for the year	(1745.52)	(1129.04)
	<b>b. Other comprehensive income of the year</b>	3.58	0.79
	<b>Closing Balance</b>	<b>(3027.14)</b>	<b>(1285.20)</b>
	Nature and purpose of reserves		
	<b>Retained earnings</b>		
	Retained earnings comprises of prior year's undistributed earnings after taxes along with current year profit.		
<b>13</b>	<b>Borrowings - Non-Current</b>		
	Unsecured-At Amortised Cost		
	Loan from Zota Health Care Limited	2064.04	1256.28
	<b>Total</b>	<b>2064.04</b>	<b>1256.28</b>
<b>14</b>	<b>Lease liabilities</b>		
	Non-current Lease obligations	6316.42	3626.31
	Current Lease obligations	1744.37	885.87
	<b>Total</b>	<b>8060.79</b>	<b>4512.17</b>
<b>15</b>	<b>Provisions -Non-Current</b>		
	Gratuity Payable	32.54	3.81
	<b>Total</b>	<b>32.54</b>	<b>3.81</b>
<b>16</b>	<b>Trade payables</b>		
	Outstanding dues of micro and small enterprises	-	-
	Outstanding dues of creditors other than micro enterprises and small enterprises	4939.80	1742.32
	<b>Total</b>	<b>4939.80</b>	<b>1742.32</b>
<b>17</b>	<b>Other Current Liabilities</b>		
	Statutory Liabilities	30.65	28.16
	Others	391.39	137.17
	<b>Total</b>	<b>422.04</b>	<b>165.32</b>
<b>18</b>	<b>Provisions - Current</b>		
	Provision for Employee Benefits	259.51	26.24
	Others	24.29	0.26
	<b>Total</b>	<b>283.80</b>	<b>26.50</b>

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**Trade receivables ageing schedule**

(₹ in Lakhs)

Particulars	Current, not due	Outstanding for following periods from due date of payment					Total
		Less than 6 Months	6 months – 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March, 31 2024</b>							
Undisputed Trade Receivables							
Considered good	-	16.48	-	-	-	-	16.48
Credit impaired	-	-	-	-	-	-	-

Particulars	Current, not due	Outstanding for following periods from due date of payment					Total
		Less than 6 Months	6 months – 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March, 31 2023</b>							
Undisputed Trade Receivables							
Considered good	-	5.01	-	-	-	-	5.01
Credit impaired	-	-	-	-	-	-	-

There are no disputed trade receivables in the current and previous year.

No trade or other receivable are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade or other receivable are due from firms or private companies respectively in which any director is a partner, a director or a member.

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

Amount ₹ in lakhs

Note No.	PARTICULARS	for the year ended 31st March, 2024	for the year ended 31st March, 2023
<b>19</b>	<b>Revenue From Operations</b>		
	Sale of Products	4476.70	1460.95
	<b>Total</b>	<b>4476.70</b>	<b>1460.95</b>
<b>20</b>	<b>Other Income</b>		
	Other Income	1.39	0.65
	<b>Total</b>	<b>1.39</b>	<b>0.65</b>
<b>21</b>	<b>Changes In Inventories Of Stock-In-Trade</b>		
	Inventories (at commencement)	720.37	114.25
	Inventories (at close)	1522.74	720.37
	<b>Total</b>	<b>(802.37)</b>	<b>(606.12)</b>
<b>22</b>	<b>Employee Benefit Expenses</b>		
	Salaries, Wages and Bonus	506.78	74.90
	Director's Remuneration	6.80	
	Contribution to Provident Fund and Other Funds	68.92	10.29
	Gratuity Expenses	34.29	3.54
	Staff Welfare Expenses	430.92	57.56
	<b>Total</b>	<b>1047.69</b>	<b>146.29</b>
<b>23</b>	<b>Depreciation and amortization expense</b>		
	Depreciation of tangible assets	328.30	177.48
	Depreciation on ROU Asset	1379.48	776.24
	<b>Total</b>	<b>1707.78</b>	<b>953.72</b>
<b>24</b>	<b>Finance Costs</b>		
	Bank Charges	26.24	4.03
	Interest Expenses - on Lease liability	415.77	245.99
	Interest On Unsecured Loan	90.97	60.91
	GLW - Interest	-	*
	<b>Total</b>	<b>532.98</b>	<b>310.93</b>
<b>25</b>	<b>Other Expenses</b>		
	<b>Administrative and General Expenses</b>		
	Audit Fees	1.00	0.25
	Advertisement Expenses	5.21	5.89
	Brokerage Expenses	6.78	14.21
	Business Promotion Expense	11.30	2.84
	Carriage Inward/Outward	5.85	1.26
	Commission Expenses	39.80	9.12
	Consultancy Charges	25.92	4.93
	Electricity Light Bill Expenses	120.96	54.05
	GST Expenses	0.16	-
	Late payment interest/penalty	0.34	0.42
	Office Miscellaneous Expense	170.26	59.23
	Hotel Exp	0.15	0.24
	Insurance Expenses	2.97	0.92
	Internal Audit Fee	2.35	1.29
	Inauguration Expenses	8.60	10.81
	Legal Expense	29.29	28.28
	Municipal Taxes	0.34	0.21
	Online Shipping & Handling Chargs	1.04	0.06



**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**26 Other Disclosures**

1 The Company has neither paid nor declared any dividend during the year.

2 Earnings Per Share

Particulars	2023-24	2022-23
Profit for the year (Rupees in lakhs)	(1745.52)	(1129.04)
No. of Equity Shares	20,00,000	20,00,000
Nominal value per share (Rupees)		
Basic and Diluted Earnings per equity share of face value of ₹ 10 each	-87.28	-56.45

3 Auditor's remuneration and expenses charged to profit and loss account are as under:

Payment to Auditor	Year ended March 31, 2024	Year ended March 31, 2023
As Auditors	1.00	0.25
In other capacities	-	-
Total	1.00	0.25

4 Income Tax

The major components of income tax expenses for the year ended March 31, 2024 and for the year ended March 31, 2023 are:

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
i. Current tax	-	-
ii Deferred tax	(334.13)	(94.76)
Total income tax expense recognised in statement of profit and loss	(334.13)	(94.76)

5 The company has not paid any managerial remuneration during the F.Y. 2023-24 and F.Y. 2022-23.

6 The Company is primarily engaged in the business of manufacturing and marketing of Pharmaceutical products. The Company has adopted Ind AS 115 'Revenue from Contracts with Customers' effective 1 April 2018. The company does not enter into contracts with customers and hence, the disclosures regarding Disaggregation of revenue and Performance obligations under Ind AS 115 are not provided.

7 Operating Segment

Based on the "management approach" as defined in Ind AS 108 – Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the Company's performance and allocates resources based on an analysis of various performance indicators of business the segment/s in which the company operates. The Company is primarily engaged in the business of manufacturing and marketing of Pharmaceutical products which the Management and CODM recognise as the sole business segment. Hence, disclosure of segment-wise information is not required and accordingly not provided.

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**8 Fair value measurements**

(₹ in Lakhs)

Financial instruments by category

Financial instruments by category	March 31, 2024			March 31, 2023		
	FVTPL	FVTOCI	Amortised cost	FVTPL	FVTOCI	Amortised cost
Financial assets						
Investments	-	-	-	-	-	-
Trade Receivables	-	-	16.48	-	-	5.01
Cash and Cash Equivalents	-	-	67.11	-	-	8.45
Other Bank Balances	-	-	12.20	-	-	15.08
Other Financial Assets	-	-	781.08	-	-	291.08
Total financial assets	-	-	876.87	-	-	319.62
Financial liabilities						
Borrowings	-	-	2064.04	-	-	1256.28
Trade Payable	-	-	4939.80	-	-	1742.32
Total financial liabilities	-	-	7003.84	-	-	2998.60

=> Fair value of financial assets/liabilities measured at amortised cost

The carrying amounts of trade receivables, cash and cash equivalents, other bank balances, current loans, other financial assets, trade payables, other financial liabilities are considered to be the same as their fair values, as they are current in nature.

**DAVAINDIA HEALTH MART LIMITED**  
**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**9. Post employment employee benefits plans**

**Gratuity**

Gratuity is payable to all eligible employees of the Company on superannuation, death and permanent disablement in terms of provisions of the Payment of Gratuity Act or as per the Company's Scheme whichever is more beneficial. Benefit would be paid at the time of separation based on the last drawn base salary.

Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity and the amounts recognised in the Company's financial statements as at the Balance Sheet date:

**Actuarial Assumptions**

Particulars	Gratuity 2023-24	Gratuity 2022-23
Discount Rate (per annum)	7.10%	7.40%
Salary Escalation rate	9.00%	9.00%
Retirement Age	60	60
Mortality	Indian Assured Lives Mortality (2012-14) Ultimate	
Employees attrition rate	5% at younger ages and reducing to 1% at older ages according to graduated scale	

**Notes:**

- 1 Estimates of future salary increase are based on inflation, seniority, promotion and other relevant factors such as demand and supply in the employment market. This assumption has been determined in consultation with the company.
- 2 Discount Rate used for valuing liabilities is based on yields (as on valuation date) of Government Bonds with a tenure similar to the expected working lifetime of the employees.

**i) Reconciliation of present value of obligations ('PVO') – defined benefit obligation:**

Particulars	2023-24 Gratuity Amount ₹ in lakhs	2022-23 Gratuity Amount ₹ in lakhs
<b>Balance at the beginning of the year</b>	<b>3.91</b>	<b>1.43</b>
Interest Cost	0.69	0.11
Current Service Cost	33.59	3.44
Benefits Paid	-	-
Actuarial (gain) / loss	(4.78)	(1.06)
<b>Balance at the end of the year</b>	<b>33.42</b>	<b>3.91</b>

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**ii) Amount Recognised in the Balance Sheet**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Present Value of Benefit Obligation	33.42	3.91
Fair Value of Plan Assets	-	-
Net Liability / (Asset) recognised in Balance Sheet	33.42	3.91

**iii) Expenses Recognised in the Income Statement**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Current Service Cost	33.59	3.44
Interest Cost on benefit obligation (net)	0.69	0.11
Expenses Recognised	34.29	3.54

**iv) Expenses Recognised in Other Comprehensive Income (OCI) for current Period**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Actuarial changes arising from changes in financial assumptions	0.99	-
Actuarial changes arising from changes in demographic adjustments	-	-
Actuarial changes arising from changes in experience adjustments	(5.76)	(1.06)
Net (Income) / Expense for period	(4.78)	(1.06)

**v) Maturity profile of defined benefit obligations**

<b>Projected Benefits Payable in Future Years From the Date of Reporting</b>	<b>2023-24 Amount ₹ in lakhs</b>	<b>2022-23 Amount ₹ in lakhs</b>
1st Following Year	0.88	0.10
2nd Following Year	0.78	0.11
3rd Following Year	0.75	0.09
4th Following Year	0.72	0.09
5th Following Year	0.74	0.09
6 to 10 years	2.65	0.29

**vi) Sensitivity Analysis Gratuity Plan**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Projected Benefit Obligation on Current Assumptions	33.42	3.91
Delta Effect of +1% Change in Rate of Discounting	27.54	3.26
Delta Effect of -1% Change in Rate of Discounting	41.15	4.77
Delta Effect of +1% Change in Rate of Salary Increase	40.92	4.75
Delta Effect of -1% Change in Rate of Salary Increase	27.58	3.26
Delta Effect of +1% Change in Rate of Employee Turnover	32.07	3.84
Delta Effect of -1% Change in Rate of Employee Turnover	35.10	4.00

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity analysis presented above may not be representative of the actual change in the projected benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the projected benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the projected benefit obligation as recognised in the balance sheet.

**vii) Risk exposure :**

Gratuity is a defined benefit plan and company is exposed to the Following Risks:

**Salary Risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of members. As such, an increase in the salary of the members more than assumed level will increase the plan's liability.

**Interest rate risk:** A fall in the discount rate which is linked to the G.Sec. Rate will increase the present value of the liability requiring higher provision.

**Asset Liability Matching Risk:** The plan faces the ALM risk as to the matching cash flow. Company has to manage pay-out based on pay as you go basis from own funds.

**Mortality risk:** Since the benefits under the plan is not payable for life time and payable till retirement age only, plan does not have any longevity risk.

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

Amount ₹ in lakhs

Note No.	P A R T I C U L A R S	for the year ended 31st March, 2024	for the year ended 31st March, 2023
	POS Charges	0.05	*
	Postage & Courier Charges	6.22	0.96
	Professional Tax	0.02	0.53
	ROC Expenses	-	0.09
	Repair and Maintenance Charges	21.40	7.46
	Sales Commission	463.11	361.65
	Shop Rent	34.56	1.24
	Voucher Reimbursement Exp	-	0.10
	Stationery and Printing Expenses	14.40	6.20
	Telephone, Internet & Mobile Bill Expense	11.40	3.70
	Transportation Charges	0.02	0.72
	Travelling Expense	1.81	2.07
		985.31	578.72
	<b>Total</b>	<b>985.31</b>	<b>578.72</b>

\* denotes figures less than a lakh

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**ii) Amount Recognised in the Balance Sheet**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Present Value of Benefit Obligation	33.42	3.91
Fair Value of Plan Assets	-	-
Net Liability / (Asset) recognised in Balance Sheet	33.42	3.91

**iii) Expenses Recognised in the Income Statement**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Current Service Cost	33.59	3.44
Interest Cost on benefit obligation (net)	0.69	0.11
Expenses Recognised	34.29	3.54

**iv) Expenses Recognised in Other Comprehensive Income (OCI) for current Period**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Actuarial changes arising from changes in financial assumptions	0.99	-
Actuarial changes arising from changes in demographic adjustments	-	-
Actuarial changes arising from changes in experience adjustments	(5.76)	(1.06)
Net (Income) / Expense for period	(4.78)	(1.06)

**v) Maturity profile of defined benefit obligations**

<b>Projected Benefits Payable in Future Years From the Date of Reporting</b>	<b>2023-24 Amount ₹ in lakhs</b>	<b>2022-23 Amount ₹ in lakhs</b>
1st Following Year	0.88	0.10
2nd Following Year	0.78	0.11
3rd Following Year	0.75	0.09
4th Following Year	0.72	0.09
5th Following Year	0.74	0.09
6 to 10 years	2.65	0.29

**vi) Sensitivity Analysis Gratuity Plan**

<b>Particulars</b>	<b>2023-24 Gratuity Amount ₹ in lakhs</b>	<b>2022-23 Gratuity Amount ₹ in lakhs</b>
Projected Benefit Obligation on Current Assumptions	33.42	3.91
Delta Effect of +1% Change in Rate of Discounting	27.54	3.26
Delta Effect of -1% Change in Rate of Discounting	41.15	4.77
Delta Effect of +1% Change in Rate of Salary Increase	40.92	4.75
Delta Effect of -1% Change in Rate of Salary Increase	27.58	3.26
Delta Effect of +1% Change in Rate of Employee Turnover	32.07	3.84
Delta Effect of -1% Change in Rate of Employee Turnover	35.10	4.00

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity analysis presented above may not be representative of the actual change in the projected benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the projected benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the projected benefit obligation as recognised in the balance sheet.

**vii) Risk exposure :**

Gratuity is a defined benefit plan and company is exposed to the Following Risks:

**Salary Risk:** The present value of the defined benefit plan liability is calculated by reference to the future salaries of members. As such, an increase in the salary of the members more than assumed level will increase the plan's liability.

**Interest rate risk:** A fall in the discount rate which is linked to the G.Sec. Rate will increase the present value of the liability requiring higher provision.

**Asset Liability Matching Risk:** The plan faces the ALM risk as to the matching cash flow. Company has to manage pay-out based on pay as you go basis from own funds.

**Mortality risk:** Since the benefits under the plan is not payable for life time and payable till retirement age only, plan does not have any longevity risk.



**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

**10. Trade payable ageing schedule**

(₹ in Lakhs)

Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March, 31 2024</b>						
Undisputed outstanding dues						
Micro enterprises and small enterprises	-	-	-	-	-	-
Others	-	3577.55	1362.24		-	4939.80
<b>Total</b>	-	3577.55	1362.24	-	-	4939.80

Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March, 31 2023</b>						
Undisputed outstanding dues						
Micro enterprises and small enterprises	-	-	-	-	-	-
Others	-	1742.32	-	-	-	1742.32
<b>Total</b>	-	1742.32	-	-	-	1742.32

**DAVAINDIA HEALTH MART LIMITED**

Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024

**11 Related Party Disclosures****i) Holding Company**

Zota Health Care Limited

**ii) Directors**

Kamlesh Rajanikant Zota

Himanshu Muktilal Zota

Moxesh Ketanbhai Zota

Viren Manukant Zota

Harkishan Ambaram Jani

**iii) Transaction with the above parties: (₹ in Lakhs)**

for the year ended 31st March, 2024	Managerial Remuneration
Harkishan Ambaram Jani	6.80

**iv) Transaction with Holding Company (₹ in Lakhs)**

for the year

ended 31st

March, 2024

for the year ended

31st March, 2023

Unsecured Loan (Value of transaction during the reporting period)	776.69	1010.87
Purchase of Goods	3156.93	1544.37

**DAVAINDIA HEALTH MART LIMITED**

Notes forming part of the standalone Financial Statements for the year ended 31st March, 2024

**12 Ratio Analysis and its elements**

(Rs. In lakhs)

S No.	Ratio	Particulars		Ratio as on	Ratio as on
		Numerator	Denominator	31-Mar-24	31-Mar-23
(a)	Current Ratio	Current Assets = Inventories + Current Investment + Trade Receivable + Cash & Cash Equivalents + Other Current Assets + Contract Assets + Assets held for Sale	Current Liability = Short term borrowings + Trade Payables + Other financial Liability+ Current tax (Liabilities) + Contract Liabilities+ Provisions + Other Current Liability	0.47	0.52
(b)	Debt-Equity Ratio <sup>1</sup>	Debt= long term borrowing + Short-term borrowings	Equity= Share capital + Reserve and Surplus	-0.68	-0.98
(c)	Debt Service Coverage Ratio <sup>2</sup>	Net Operating Income= Net profit after taxes + Non-cash operating expenses + finance cost	Debt Service = Interest & Lease Payments + Principal Repayments	0.34	0.16
(d)	Return on Equity Ratio <sup>3</sup>	Net Income= Net Profits after taxes – Preference Dividend	Shareholder's Equity	0.62	0.88
(e)	Inventory Turnover Ratio	Sales	(Opening Inventory + Closing Inventory) /2	3.99	3.50
(f)	Trade Receivables Turnover Ratio	Net Credit Sales	(Opening Trade Receivables + Closing Trade Receivables) /2	416.53	538.77
(g)	Trade Payables Turnover Ratio <sup>4</sup>	Net Credit Purchases	(Opening Trade Payables + Closing Trade Payables) /2	0.92	1.32
(h)	Net Capital Turnover Ratio	Net Sales	Current assets – Current liabilities	-1.14	-1.07
(i)	Net Profit Ratio <sup>5</sup>	Net Profit	Net Sales	-0.39	-0.77
(j)	Return on Capital Employed	EBIT= Earnings before interest and taxes	Capital Employed= Total Assets - Current Liability	-0.28	-0.24
(k)	Return on Investment <sup>6</sup>	Net Profit	Net Investment= Net Equity	0.62	0.88

Explanation for Change in the Ratio by more than 25% as compared to previous year:

- 1 For aggressive expansion of Company Owned Company Operated (COCO) stores of Davaindia, the Company has taken unsecured loan from the holding Company Zota Health Care Limited, resulted in increase in borrowings.
- 2 Due to loss incurred in the current financial year and increase of lease payments due to new COCO stores addition in the current financial year.
- 3 Robust expansion of COCO stores has resulted in huge operating expenses, henceforth the Company has incurred net loss in the current financial year.
- 4 Due to robust expansion of the COCO stores, the net purchase has been increase drastically resulted increase in the trade payable.
- 5 During the year, the Company has added new 154 COCO stores resulted increase in the operational expenses and resulted increase in the net loss during the year.
- 6 Expansion of COCO stores has resulted into widen the net losses in the current financial year and also increased in the capital employed as compared to preceeding financial year.

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

- 13 Previous year's figures have been regrouped / recast wherever necessary to conform to current interim period's presentation.
- 14 The Company has no dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) as on 31/03/2024. Hence no reporting is required.
- 15 All known liabilities have been provided for in the books of accounts for the financial year 2023-24.
- 16 The Company does not have any contingent liabilities for the financial year 2023-24. (Previous year- Nil)
- 17 The code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September, 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is in the process of assessing the impact of the Code and will record the same, if any, in the year the Code becomes effective.
- 18 The provisions of section 135 of the Companies Act, 2013 with respect to CSR are not applicable to the Company.
- 19 The company has not imported any goods or services during the Financial Year 2023-24 and Financial Year 2022-23.
- 20 The company has not incurred any expenditure in Foreign Currency during the Financial Year 2023-24 and Financial Year 2022-23.
- 21 The company does not have any earnings in Foreign Currency during the Financial Year 2023-24 and Financial Year 2022-23.
- 22 Additional regulatory information required by schedule III to the Companies Act, 2013

The Company does not own any immovable property hence, disclosure relating to the title deeds of immovable properties is not required.

The Company does not have any benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

The Company has not traded or invested in crypto currency or virtual currency during the year.

The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries

**DAVAINDIA HEALTH MART LIMITED**

**Notes forming part of Standalone financial statements as at and for the year ended 31st March, 2024**

The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like on behalf of the ultimate beneficiaries

The company does not have layers of subsidiaries beyond the prescribed number with respect to the Companies (Restriction on number of layers) Rules, 2017.

The Company did not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

The Company does not have any transactions with companies struck off.

The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

- 27** These Financial Statements were authorised for issue in accordance with the resolution of the Board of Directors in its meeting held on 20th May, 2024.

Signatures to Notes 1 to 27

**For and on behalf of the Board**

**For Poonam Murarka And Associates**  
**Chartered Accountants**  
**Firm No. 153909W**

(Director)  
**Himanshu M. Zota**  
(Din : 01097722)  
**34, Ichhanath Umra,**  
**Surat.,**

(Director)  
**Moxesh K. Zota**  
(Din : 07625219)  
**8D, Lal Bunglow, Athwalines,**  
**Surat.,**

**Poonam Murarka**  
**Proprietor**  
**M. No. 188906**